Introduction {#s1}
============

Depression is a chronic, prevalent, and debilitating mental illness that influences 15--20% of the population over the globe ([@B25]). According to a recent report by the World Health Organization, depression is the leading cause of disability and a major contributor to the general burden of illness ([@B81]). Therefore, development of effective antidepressants will provide enormous social, economic, and health benefits.

Depression is not a unified syndrome, in which multiple underlying mechanisms exist. It is impossible to identify a specific factor that leads to or stops depression in all patients ([@B72]). Hence, the better healing approach could be to seek the unique cause for each individual patient and then to apply a personalized treatment, not only for alleviating depression, but also for correcting the body\'s dysfunction that triggers depressive symptoms ([@B101]).

TCM in Depression Treatment {#s2}
===========================

The conventional antidepressants with single targets are insufficient and far from ideal. TCM has historically been used to treat depression up till today in clinical practice, particularly in Asia. TCM is a holistic medicine, which emphasizes the integrity of body and environmental effects on the internal homeostasis. In TCM, depression is thought to result from "vital energy" deficiency that is caused by dysfunction of multiple physiological systems in the body, such as dysregulation of blood circulation, inflammation, or "dampness and phlegm" ([@B96]). Strengthening "vital energy" is its healing principle, but correction of imbalance in other physiological systems by stimulating blood circulation, restraining inflammation, or removing "phlegm and dampness" is also needed ([@B15]).

It is well-known that a TCM herbal formula is more effective than single herbal molecules or herbs in clinical practice. There are numerous TCM herbal formulas, such as Kai-Xin-San (KXS), that have been usually used for depression treatment. Each formula is a mixture of multiple herbs that are proposed to act on diverse pathological targets simultaneously. Their composition and dosage rely on symptoms of individual patients. The holistic, multidrug, and multitarget nature of TCM fits well with the healing idea of systems medicine in the treatment of complex diseases, such as depression.

During the past two decades, efforts have been made to understand TCM in depression treatment; however, many fundamental questions regarding their mechanisms of action remain to be addressed. Previous studies have focused on revealing the mechanism of action at the molecular level by using either single herbal molecules or extracts from single herbs because the constituent complexity and drug--drug interactions of an entire formula often obstruct to uncover the molecular mechanism of action. However, it is vital to integrate the mechanism of action from the molecule level into the systems level in order to elucidate the system-wide mechanism of action of an herbal formula. The remarkable progress in our understanding of neurobiology of depression provides an opportunity to interpret the mechanism of action of herbal formulas at the systems level.

Studies have revealed many divergent biological systems that are implicated in the pathophysiology of depression ([@B12]). These findings have provided numerous pharmacological targets that have been translated into the foundation to reveal the mechanism of action of antidepressants. In this *Mini Review*, we review and discuss the influences of herbal antidepressants on the pathological systems in the CNS ([**Figure 1**](#f1){ref-type="fig"}), as well as the pharmacological approaches to integrate the mechanism of action of TCM antidepressant formulas from the molecular level into the systems level. A preliminary literature search for TCM herbal antidepressants was performed on the PubMed, Ovid, Google Scholar, and China National Knowledge Infrastructure and WanFang database by using keywords (Traditional Chinese medicine and depression or antidepressant and the term corresponding to the specific mechanism of action, such as monoamine transmission, HPA axis, BDNF, or rapid-acting antidepressant) without language restriction. Abstracts under the same mechanism of action category were independently screened by authors to identify articles of interest and full articles were further selected as representatives with a priority for single herbal molecules or herbs in the latest publications. Given space limitations, this review is not comprehensive; rather we give a few representative herbal molecules that are related to KXS (except for glutamate transmission) and well interpreted at the molecular level, and other herbal molecules are listed with a structural classification in [**Table 1**](#T1){ref-type="table"}.

![Several divergent systems in the CNS are involved in the pathophysiology of depression. The pathophysiological systems in the CNS that herbal antidepressants are proposed to act on include monoamine neurotransmissions, the HPA axis, neurotrophins, and synapse number and function as shown. Dysfunction of these systems leads to increased incidence of depression. Correspondingly, antidepressant discovery efforts toward these systems have provided numerous pharmacological targets, which include enhancement of monoaminergic transmissions, dehyperactivation of HPA axis, elevation of neurotrophic factor expression, and stimulation of glutamatergic transmission. Given space limitations, other factors in the pathophysiology of depression, such as the proinflammatory cytokines, the gastrointestinal system, ovarian steroids, vascular endothelial growth factor, and gene polymorphisms are not shown and discussed in this *Mini Review*.](fphar-11-00586-g001){#f1}

###### 

Herbal constituents that produce antidepressant-like activities in animal models or cells.

  Structural category                 Herbal constituents                                                 Herbs                                           Mechanism of action              Models                      Administration dosage     Treatment time      Reference
  ----------------------------------- ------------------------------------------------------------------- ----------------------------------------------- -------------------------------- --------------------------- ------------------------- ------------------- -----------
  **Saponins**                        Total saponins                                                      *Panax ginseng* C. A. Mey.                      The HPA axis/BDNF                CUMS rats                   12.5, 25,50 mg/kg, i.g.   6 weeks             ([@B50])
  Sarsasapogenin                      *Anemarrhena asphodeloides* Bunge                                   Monoamine                                       CUMS mice                        12.5, 25, 50 mg/kg, p.o.    14 days                   ([@B65])            
  Ginsenoside Rb~1~                   *Panax ginseng* C. A. Mey.                                          Monoamine                                       mice                             4, 8, 16 mg/kg, p.o.        7 days                    ([@B76])            
                                                                                                                                                          mice                             5, 10, 20 mg/kg, p.o.       60 min                    ([@B78])            
                                                                                                          BDNF                                            CUMS mice                        20 mg/kg, p.o.              21 days                   ([@B79])            
  Ginsenoside Rg3                     *Panax ginseng* C. A. Mey.                                          The HPA axis                                    CUS rats                         20, 40 mg/kg, i.g.          14 days                   ([@B90])            
                                                                                                          BDNF                                            CSDS mice                        10, 20 mg/kg, i.p.          14 days                   ([@B98])            
                                      *Panax notoginseng* (Burkill) F. H. Chen ex C. Chow & W. G. Huang   Glutamate transmission/BDNF                     CMS mice                         50, 100, 150 mg/kg, i.g.    4 weeks                   ([@B105])           
  Ginsenoside Rg1                     *Panax ginseng* C. A. Mey.                                          BDNF                                            CUMS rats                        40 mg/kg, i.p.              5 weeks                   ([@B54])            
  Ginsenoside Rg5                     *Panax ginseng* C. A. Mey.                                          BDNF                                            CSDS mice                        5, 10, 20, 40 mg/kg, i.p.   14 days                   ([@B88])            
  Saikosaponin A                      *Bupleurum chinense* DC.                                            Monoamine                                       CUMS rats                        50 mg/kg, i.g.              4 weeks                   ([@B24])            
  Saikosaponin D                      *Bupleurum chinense* DC.                                            The HPA axis                                    CUMS rats                        0.75 and 1.50 mg/kg, i.g.   21 days                   ([@B48])            
  YY-21                               *Anemarrhena asphodeloides* Bunge                                   BDNF                                            CMS rats                         10 mg/kg, i.g.              3 weeks                   ([@B23])            
  YY-23                               *Anemarrhena asphodeloides* Bunge                                   Glutamate transmission                          CMS mice                         20 mg/kg, i.g.              3 weeks                   ([@B104])           
  Yuanzhi-1                           *Polygala tenuifolia* Willd.                                        Monoamine                                       CMS rats                         2.5, 5, 10 mg/kg, p.o.      38 days                   ([@B33])            
  YZ-50                               *Polygala tenuifolia* Willd.                                        BDNF                                            CMS rats                         140 and 280 mg/kg, i.g.     28 days                   ([@B26])            
  Icariin                             *Epimedium brevicornu* Maxim.                                       The HPA axis                                    SDM mice                         25 and 50 mg/kg, i.g.       28 days                   ([@B83])            
  20(*S*)‐protopanaxadiol             *Panax ginseng* C. A. Mey.                                          BDNF                                            CSDS mice                        20 and 40 μmol/kg, i.p.     14 days                   ([@B30])            
  **Glycosides**                      Salidroside                                                         *Rhodiola rosea* L.                             The HPA axis/BDNF                Behavioral despair rats     20, 40 mg/kg, p.o.        14 days             ([@B95])
  Total glycosides                    *Paeonia lactiflora* Pall.                                          BDNF                                            CORT-induced rats                160 mg/kg, p.o.             21 days                   ([@B57])            
  Gentiopicroside                     *Gentiana lutea* L.                                                 Glutamate transmission                          Reserpine-induced mice           50, 100, 200 mg/kg, i.g.    3 days                    ([@B53])            
  Gastrodin                           *Gastrodia elata* Bl.                                               BDNF                                            CUS rats                         50, 100, 200 mg/kg, i.p.    14 days                   ([@B103])           
  Paeoniflorin                        *Paeonia lactiflora* Pall.                                          BDNF                                            CUMS mice                        20 mg/kg, i.p.              30 days                   ([@B55])            
  **Flavonoids**                      Flavonoid Extract                                                   *Apocynum venetum* L.                           BDNF                             CORT-induced PC12 Cells     25, 50, 100 μg/ml         48 hours            ([@B110])
  Pueraria isoflavone                 *Pueraria lobate* (Willd.) Ohwi                                     BDNF                                            Ovariectomy mice                 10 and 100 mg/kg            8 weeks                   ([@B69])            
  Puerarin                            *Pueraria lobate* (Willd.) Ohwi                                     Monoamine/the HPA axis                          CUS rats                         60 and 120 mg/kg, i.g.      20 days                   ([@B63])            
                                                                                                          BDNF                                            Perimenopausal depression mice   30, 60, 120 mg/kg, i.g.     8 or 14 days              ([@B109])           
  Curcumin                            *Curcuma longa* L.                                                  Monoamine/the HPA axis/BDNF                     CUMS rats                        2.5, 5 and 10 mg/kg, p.o.   21 days                   ([@B87])            
                                                                                                                                                          CUMS rats                        40 mg/kg, i.p.              6 weeks                   ([@B102])           
                                                                                                                                                          WKY rats                         50, 100, 200 mg/kg, i.p.    10 days                   ([@B29])            
  Genistein                           *Glycine max* (L.) Merr.                                            Monoamine                                       Mice                             5, 15, 45 mg/kg, p.o.       3 weeks                   ([@B28])            
  Baicalein                           *Scutellaria baicalensis* Georgi                                    BDNF                                            CMS rats                         1, 2, 4 mg/kg, i.p.         21 days                   ([@B86])            
  **Alkaloids**                       Isorhynchophylline                                                  *uncaria rhynchophylla* (Miq.) Miq. ex Havil.   Monoamine                        Mice                        10, 20, 40 mg/kg, i.g.    7 days              ([@B85])
  Berberine Chloride                  *Berberis aristata* Linn.                                           Monoamine                                       Male albino mice                 5, 10, 20 mg/kg, i.p        15 days                   ([@B40])            
  Piperine                            *Piper Nigrum* L. *Piper longum* L.                                 BDNF                                            CORT-induced mice                5, 10 mg/kg, i.p.           21 days                   ([@B58])            
  Tetrandrine                         *Stephania tetrandra* S. Moore                                      Monoamine/BDNF                                  CUMS rats                        10, 20, 40 mg/kg, i.g.      2 weeks                   ([@B20])            
  Total alkaloid                      *Aconitum carmichaelii* Debeaux                                     BDNF                                            Ovariectomized mice              10, 30 mg/kg, i.g.          7 days                    ([@B51])            
  Scopolamine                         *Solanaceae* Juss.                                                  Glutamate transmission                          *Gad1-Cre Camk2a-Cre* mice       25 μg/kg, i.p.              48 hours/3 times          ([@B82])            
  Huperzine A                         *Huperzia* Bernh.                                                   Monoamine/BDNF/Glutamate transmission           *CUMS rats*                      0.05 and 0.15 mg/kg, i.g.   4 weeks                   ([@B111]; [@B11])   
  **Carbohydrates**                   Oligosaccharide                                                     *Morinda officinalis* How                       The HPA axis                     CORT-induced PC12 cells     5, 10, 125, 500 μM        5 days              ([@B43])
                                                                                                                                                          CUS mice                         12.5, 25, 50 mg/kg, i.g.    14 days                   ([@B89])            
  Fuzi polysaccharide 1               *Aconitum carmichaelii* Debeaux                                     BDNF                                            Mice                             50, 100 mg/kg, i.p.         14 days                   ([@B92])            
  Chiisanoside                        *Acanthopanax* Miq.                                                 BDNF                                            LPS-induced mice                 2.5 and 5 mg/kg, i.p.       7 days                    ([@B3])             
  **Anthraquinones**                  Emodi                                                               *Rheum palmatum* L.                             BDNF                             CUMS mice                   20, 40, 80 mg/kg, i.g     21 days             ([@B47])
  **Terpenes and Phenylpropanoids**   Resveratrol                                                         *Polygonum cuspidatum* Siebold et Zucc.         Monoamine                        depression mice             30 mg/kg, p.o.            3 weeks             ([@B108])
                                                                                                          The HPA axis/BDNF                               Mice                             20, 40, 80 mg/kg, i.p.      21 days                   ([@B75])            
                                                                                                          BDNF                                            LPS-induced mice/CUMS rats       80 mg/kg, i.p.              7 days/5 weeks            ([@B52]; [@B21])    
  Trans-resveratrol                   *polygonum cuspidatum* Siebold et Zucc.                             Monoamine                                       CUS rats                         40, 80 mg/kg, i.g.          21 days                   ([@B99])            
  Rosmarinic acid                     *Perilla frutescens* (L.) Britt.                                    BDNF                                            CUS rats                         5 and 10 mg/kg, i.p.        14 days                   ([@B31])            
  Crocin                              *Crocus sativus* L.                                                 BDNF                                            Rats                             12.5, 25, 50 mg/kg, i.p.    21 days                   ([@B71])            
  Cucurbitacin IIa                    *Hemsleya amabilis* Diels                                           BDNF                                            CUMS mice                        2.5, 5 mg/kg, i.p.          5 weeks                   ([@B114])           
  Hyperforin                          *Hypericum perforatum* L.                                           BDNF                                            mice                             4 mg/kg, i.p.               4 weeks                   ([@B22])            
                                                                                                          Glutamate transmission                          Cortical neurons of rats         10 µM                       9-12 days                 ([@B41])            
  Bakuchiol analogs                   *Psoralea corylifolia* Linn.                                        Monoamine                                       Tr-CHO cells                     0.03-333 µM                 20 min                    ([@B107])           
  Honokiol                            *Magnolia officinalis* Rehd. et Wils.                               The HPA axis/BDNF                               CUMS rats                        2, 4, 8 mg/kg, i.g.         21 days                   ([@B77])            
  Macranthol                          *Illicium dunnianum* Tutch.                                         BDNF                                            CUMS mice                        10, 20, 40 mg/kg, p.o.      5 weeks                   ([@B46])            

Herbal constituents are listed according to their structural category and their sources, mechanism of action, animal models, and administration dosage and time are also given. Although TCM formulas have been shown to work more efficiently than single constituents or herbs in clinical practice, single molecules or herbs are often used for interpreting the mechanism of action at the molecular level due to the constituent complexity and drug--drug interactions of TCM formulas. For understanding the mechanism of action of a TCM formula at the systems level, it is essential to integrate the molecular mechanism into the system-wide mechanism of action. The representative TCM formulas in depression treatment are, but no limited to, Xiao-Yao-San ([@B5]), Kai-Xin-San ([@B18]), Jie-Yu-Wan ([@B16]), Shu-Yu-San ([@B6]), Chaihu-Jia-Longgu-Muli-Tang ([@B44]), and so on. CUMS, chronic unpredictable mild stress; CSDS, chronic social defeat stress; CMS, chronic mild stress; SDM, social defeat model; CORT, corticosterone; CUS, chronic unpredictable stress; WKT, Wistar Kyoto; LPS, lipopolysaccharides.

Molecular Mechanism of Action of TCM Herbal Antidepressants {#s3}
===========================================================

Monoamine Transmissions {#s3_1}
-----------------------

In monoamine hypothesis, depression is caused by an impairment of monoamine neurotransmissions. Inhibition of monoamine reuptake transporters increases the availability of monoamines in the synaptic cleft and subsequently enhances monoamine transmissions. The monoamine reuptake transporters for serotonin (5-HT) and norepinephrine (NE) are the major targets for current available antidepressants. In addition, a host of proteins including monoamine metabolic enzymes and postsynaptic monoamine receptors are also involved in monoamine transmissions. The monoamine-based inhibitors enhance 5-HT or NE transmission, resulting in alterations in firing activity of dorsal raphe nucleus or locus coeruleus through different mechanisms ([@B56]; [@B2]).

It can be exemplified with the study on *Polygala tenuifolia* Willd., which has been shown to exert expectorant, tonic, tranquilizer and antipsychotic efficacies in clinical practice and can be seen in several empirical formulas for depression treatment, such as Kai-Xin-San (KXS) ([@B27]). Its mechanism of action in depression treatment had not been well understood until Yuanzhi-1, a triterpenoid saponin isolated from *Polygala tenuifolia* Willd., has recently been identified to be a triple monoamine reuptake inhibitor with a high potency ([@B33]). Moreover, Yuanzhi-1 and its several derivates have been shown to exert comparable antidepressant-like activities with the conventional antidepressant, duloxetine, in animal behavioral models ([@B32]). However, lack of selectivity for 5-HT or NE reuptake of these triterpenoid saponins increases our concerns about their addictive side effects caused by elevating synaptic concentrations of dopamine. Hence, it is interesting to know if there are some constituents that show antagonistic interactions with the triterpenoid saponins to normalize their effects on dopamine transmission in *Polygala tenuifolia* Willd.-containing formulas. In addition to its influence on monoaminergic systems, previous studies have shown that an oligosaccharide esters-enriched fraction YZ50 produces an antidepressant action in animal models through the HPA axis ([@B26]; [@B49]). These results indicate that *Polygala tenuifolia* Willd. possesses various antidepressant actions through multiple mechanisms. Therefore, further study to reveal the synergistic interactions between the constituents is required in order to integrate their effects on multiple biological systems into the system-wide mechanism of action of *Polygala tenuifolia* Willd.

Besides Yuanzhi-1 and its derivates, many other herbal molecules have also been shown to produce antidepressant-like activities through their impacts on monoamine transmission, although their pharmacological profiles have not been clearly revealed yet ([**Table 1**](#T1){ref-type="table"}). These compounds, ranging from polyphenols, saponins, alkaloids, and flavonoids, have no structural preference in their mechanisms of action underlying enhancement of monoamine transmissions.

The HPA Axis {#s3_2}
------------

Stress leads to activation of the HPA axis usually reflected in high levels of glucocorticoids, which subsequently impair neuronal survival and neurogenesis and thereby result in depressive symptoms ([@B35]). It should be emphasized that the communications exist between the HPA axis and the CNS, endocrine, or immune system by neural, hormonal, or inflammatory interactions, and that these systems integrate into a network that underlies antidepressant action. For instance, monoamine-based antidepressants can not only reverse stress-induced hyperactivity of the HPA axis, but also attenuate the inflammatory changes by reducing the release of proinflammatory cytokines from activated microglia ([@B42]; [@B64]; [@B67]). Similarly, agents that eliminate inflammatory effects also exert an antidepressant-like activity in animal models through the communication between the CNS and immune system ([@B120]). Furthermore, agents that directly target the HPA axis, such as glucocorticoid receptor antagonists, vasopressin receptor antagonists, and corticotropin-releasing hormone receptor antagonists, could also be effective antidepressants by blocking receptor activities to terminate the consequence of hormone secretions due to stress-induced hyperactivity of the HPA axis ([@B59]).

Ginsenoside Rg3, a protopanaxadiol ginsenoside from *Panax ginseng* C. A. Mey., has been recently reported to exert anxiolytic and antidepressant-like activities through dehyperactivation of the HPA axis by reducing corticotropin releasing hormone, corticosterone and adrenocorticotropic hormone in chronic unpredictable stress (CUS) animal models ([@B90]). Interestingly, a previous study demonstrated that this compound produces anti-inflammatory activities by reducing the level of inflammatory cytokines in the lipopolysaccharide-induced mice ([@B34]). This phenomenon of one herbal molecule with multiple functions is often seen in the study of herbal antidepressants, possibly due to either the crosstalk between the biological systems or nonspecific interactions with multiple systems.

Other herbal constituents have also been reported to produce antidepressant-like activities through their effects on the HPA axis ([**Table 1**](#T1){ref-type="table"}). However, all of these herbal constituents have not been clarified whether their effects are direct or indirect. We cannot exclude one scenario that herbal constituents could directly act on one biological system and then induce the responses from the HPA axis due to the cross-talk between these biological systems. Thus, it could obscure the pharmacological targets that herbal constituents actually act on and mislead us to understand their molecular mechanisms of action. Therefore, further studies are needed to clarify the contribution of herbal constituents to the system-wide antidepressant action.

Neurotrophins {#s3_3}
-------------

Brain-derived neurotrophic factor (BDNF) deficiency contributes to the pathophysiology of depression ([@B13]). Experimental observations have demonstrated that stress-induced downregulation of cAMP response element binding protein (CREB) mRNA level, and its phosphorylation, BDNF expression, and neurogenesis can be reversed by antidepressant treatments ([@B36]). This raises the possibility that an agent that directly stimulates BDNF singling cascade might be an effective antidepressant. The potential drug targets in BDNF cascade should enhance CREB activity and BDNF expression, activate BDNF receptor TrkB, or stimulate post-receptor signaling cascades such as Ras-Raf-ERK, PI3K-Akt, and PLC*γ*.

Recent studies have demonstrated that chronic administration (40 mg/kg, 5 weeks) of ginsenoside Rg1, a protopanaxatriol type of ginsenoside, reverses behavioral abnormality and downregulation of the phosphorylation level of CREB and BDNF expression in the prefrontal cortex induced by chronic unpredictable mild stress (CUMS) in rats ([@B117]; [@B100]). In addition, ginsenoside Rg1 has also been shown to exert neuroprotective effects by suppressing inflammatory pathway activity, inhibiting neuronal apoptosis, and stimulating synaptic-related protein expression, such as CREB, BDNF, PSD-95, and synaptophysin ([@B14]). Ginsenoside Rg5, a protopanaxadiol ginsenoside, has been reported to exert an antidepressant-like activity by reversing the chronic social defeat-induced decrease in hippocampal BDNF expression and phosphorylation of TrkB ([@B88]).

Several other herbal constituents have also been reported to produce antidepressant-like activities through BDNF signaling cascade ([**Table 1**](#T1){ref-type="table"}). It will be interesting to know if these herbal constituents directly act on BDNF signaling cascade and what targets they specifically interact with. Hence, more in-depth studies are required to address these questions, which are important for our understanding of their mechanistic details in order to further refine the use of these herbal antidepressants.

Glutamate Transmission {#s3_4}
----------------------

Glutamate transmission has recently received the most attention in the development of rapid-acting antidepressant agents. These agents, such as NMDA receptor channel blockers and its positive allosteric modulators and acetylcholine muscarinic (AChM) receptor antagonists, enhance glutamate transmission, subsequently increase BDNF release and synapse function, thus rapidly reverse stress-induced synaptic abnormalities ([@B38]; [@B44]; [@B4]). Ketamine, a NMDA receptor antagonist, has been shown to produce rapid antidepressant actions ([@B8]; [@B61]), and its *S* (+) enantiomer, esketamine was approved in 2019 as the first rapid-acting antidepressant to treat severe depression.

The *Solanaceae* Juss. family of herbs such as *Datura metel* L.*, Hyoscyamus niger* L., and *Datura stramonium* L. contain psychedelic tropane alkaloids used for surgical anesthesia in ancient TCM practice. Scopolamine, a major tropane alkaloid isolated from these herbs, can readily cross the brain blood barrier into the CNS to inhibit AChM1 receptor ([@B37]). Recent studies have demonstrated that a single dose of scopolamine (25 µg/kg) exerts rapid antidepressant actions within days in rats ([@B19]; [@B10]). Its antidepressant actions have been revealed to be mediated through blockade of AChM1 receptor on GABA interneurons and subsequently to increase in glutamate transmission and function of spine synapse ([@B73]; [@B82]; [@B17]).

In addition to scopolamine, two herbal formulas, Yueju pill and Chaihu-jia-Longgu-Muli-tang, have recently been reported to exert rapid-acting antidepressant-like activities in animal models. A dose of ethanol extracts from Yueju pill (3 g/kg) rapidly attenuated depressive-like behaviors, increased hippocampal BDNF expression, activated prefrontal Akt-mTOR signaling, and downregulated NR1 expression within days ([@B91]; [@B68]; [@B84]). Chaihu-jia-Longgu-Muli-tang (a single dose of 2.1 g/kg) has also been shown to produce a rapid antidepressant-like activity in olfactory bulbectomization mice through activation of Akt-mTOR signaling and normalization of AMPA receptor/NMDA receptor ratio in PFC ([@B80]). In addition, these formulas have previously been shown to produce antidepressant actions through monoaminergic systems as well as the HPA axis in chronic animal models ([@B60]; [@B45]; [@B75]). It is reasonable that these formulas possess multiple antidepressant actions through several underlying mechanisms due to its multidrug property, but further study is needed to reveal the synergistic interaction between its rapid antidepressant action and other underlying mechanisms.

Transition from Molecules to Systems {#s4}
====================================

Studies have revealed numerous pathological factors that are involved in the pathophysiology of depression ([@B39]). In addition to the factors or systems in the CNS mentioned above, other notable factors include proinflammatory cytokines, ovarian steroids, gastrointestinal system and microbiome, and vascular endothelial growth factor ([@B66]). The CNS-orientated and single target antidepressants can only be used to alleviate depressive symptoms, but not to correct dysfunction of the pathological factors in other biological systems. On the other hand, the holistic and multidrug approach of TCM formulation is proposed to simultaneously act on multiple targets across various systems in the pathophysiology of depression. Therefore, it is essential to investigate the mechanism of action at the systems level for better understanding of TCM formulations in depression treatment.

It is a challenge to investigate the pharmacology of any TCM formulation at the systems level, including synergistic interaction and compatibility between herbs within multiherb combinations, due to the fact that not all potentially bioactive ingredients from any given TCM formula were identified and that their pharmacological properties were not thoroughly defined ([@B113]). However, several studies have successfully been conducted to examine the synergistic, additive, and antagonistic interactions of herb pairs in complex TCM formulas ([@B1]; [@B97]; [@B74]). KXS, a combination of four herbs (*Panax ginseng* C. A. Mey., *Polygala tenuifolia* Willd., *Acorus tatarinowii* Schott, and *Poria cocos* (Schw.) Wolf), is an empirical formula for depression treatment. A recent study has been performed to optimize the compatibility of herb pairs in KXS by examining the activation of neurofilament expression in PC12 cells ([@B93]). In this study, *Panax ginseng* C. A. Mey. and *Polygala tenuifolia* Willd. were placed as an herb pair with a function in invigorating "vital energy", while *Acorus tatarinowii* Schott and *Poria cocos* (Schw.) Wolf were assigned to another pair to eliminate "dampness and phlegm". The study showed that an optimized KXS with an herb pair ratio (1:5) produced the greatest capability in promoting the expression of neurofilament and that two herb pairs exert strong synergistic interactions in stimulating neuronal differentiation.

KXS has previously been demonstrated to exert antidepressant actions through multiple mechanisms across biological systems, including increase in monoamine availability ([@B112]; [@B116]), activation of hippocampal synaptogenesis and BDNF signaling cascade ([@B118]; [@B94]; [@B119]), dehyperactivation of the HPA axis ([@B7]), and enhancement of lipid metabolism ([@B115]). It is evident that the antidepressant efficiency of KXS results from the synergistic interactions between individual herbs, although each herb showed the potent effect in depression treatment ([@B93]). A recent study has been conducted to screen the proteins in response to KXS administration (0.6 g/kg, 14 days) across biological systems by using quantitation-based proteomics ([@B9]). In this study, total 33 proteins with altered expression levels were identified to be associated with KXS treatment. Functional analysis further revealed that these proteins are implicated in glutamate signaling, synaptic plasticity, metabolic process, cell survival process, and BDNF, mTORC1, and cAMP pathways. These studies indicated that KXS exerts antidepressant actions across multiple biological systems and provided pharmacological approaches to our understanding of the mechanism of action of KXS at the systems level.

Discussion {#s5}
==========

The studies, in which the herbal constituents or single molecules were used for exploring the mechanism of action at the molecular level, have provided a foundation to understand the system-wide mechanism of action of an herbal formula. Systems pharmacology studies drugs, drug targets, and drug effects at the systems level and reveals all responses across various biological systems to the pharmacological action of drugs ([@B106]). Therefore, application of systems pharmacology approaches to TCM study is vital for our understanding of the system-wide mechanism of action of herbal formulas.

Although single herbal molecules or herbs show the potent action in depression treatment, an herbal composite formula is used clinically, rather than a single form. The empirical formulas have been proven to have greater efficacy and safety than single drugs in clinical practice, possibly due to their synergistic interactions and mutual detoxification ([@B70]). The synergy of multiple herbs in an herbal formula could be triggered by the interactions between herbal molecules from different herbs or between the pharmacological targets across biological systems that herbal molecules specifically act on, and this phenomenon could be interpreted through systems pharmacology study of TCM herbal formulations.

We should acknowledge that a major challenge is lack of an integrated database including all interactions between the pathological factors across biological systems in the pathophysiology of depression, although efforts have been made to identify the specific interactions within the CNS ([@B62]). The effects of other biological systems on the CNS remain to be thoroughly studied in order to reveal the interactions between the pathological factors in different biological systems. With such a database, we will be able to promote our study from the molecular level into the systems level, which, in turn, could facilitate the integration of other biological systems with the CNS in depression treatment.

In summary, integration of the studies at the molecular level into the systems level not only represents a trend in TCM study but also promotes our understanding of the system-wide mechanism of action of herbal formulas. With many available techniques in systems biology, neurobiology, and pharmacology, the study of TCM will assist in developing future medications or approaches for systematic and effective depression treatment.
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